Articles On Proteomics International Laboratories (ASX:PIQ)

Mixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch its predictive diabetes test next year Chimeric raises $5 million – but drops its daks to do so   As the end-of-October quarterly reporting...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

Health Check is renowned biotech journo Tim Boreham’s daily wrap covering morning movers and shakers of note in the ASX Healthcare sector, Monday through Thursday.   Proteomics blood-based test showed 94% accuracy in both detecting and rul...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 8168.00 + 53.00 0.65% S&P ASX 200 8121.60 +...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 8116.00 + 16.00 0.20% S&P ASX 200 8099.90 +...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 8119.00 + 49.00 0.61% S&P ASX 200 8075.70 +...

  ASX falls on Wednesday with banks dragging down market Lithium stocks surge on CATL suspension reports; MinRes hits new high Energy stocks struggle as Brent drops below US$70   The ASX was on the back foot on Wednesday, down by 0.3%  w...

The ASX200 has been down 0.3% at 7,988 points in early afternoon trade. Gold prices have climbed back to record levels during the US Trump-Harris Presidential debate on Wednesday morning, just under $2,520 per ounce American. Futures...

Proteomics International Laboratories Ltd (ASX:PIQ) has seen its share price plunge more than 20% on news that it has ended its exclusive agreement with Sonic Healthcare USA relating to the use and commercialisation of PromarkerD – its pred...

Proteomics and US partner Sonic Healthcare say ‘I don’t’ and go their separate ways The company hopes to launch its PromarkerD diagnostic tool in the US in the current financial year Virtual health IT provider Visionflex VFX has unveiled t...

Proteomics International Laboratories’ “PromarkerD” device that uses a simple finger-prick blood test has shown a high accuracy in being able to predict future kidney disease in type 1 diabetes patients.

Proteomics International Laboratories (ASX: PIQ) has obtained what it describes as “groundbreaking” results in its development of treatments for deadly type 1 diabetes. More than 130,000 Australians live with type 1 diabetes, which currentl...

Proteomics International Laboratories has sealed a new deal with medical diagnostics company Eurobio Scientific to distribute its predictive “PromarkerD” test for diabetic kidney disease in France.

Proteomics International Laboratories is escalating its expansion into the European market after appointing sales agency Growth Medics to promote its “PromarkerD” predictive test for diabetic kidney disease.

Predictive diagnostics medical company Proteomics International Laboratories (ASX: PIQ), has engaged Growth Medics B.V., to assist with the identification and selection of EU alliance partners for its PromarkerD predictive test for diabetic...

Having served as Proteomics chief since he co-founded the company in 2001, Dr Richard Lipscombe is used to setbacks and delays. On March 18, Proteomics (ASX:PIQ) said it would not be able to meet the June 2024 timeline for the US launch of...

Research conducted by Proteomics International Laboratories and Curtin University has made a crucial discovery in understanding how dieback impacts plants in a potentially significant agriculture breakthrough.

Predictive diagnostics specialist Proteomics International Laboratories (ASX: PIQ) has signed an agreement with the University of Oxford to acquire approximately 600 patient plasma samples for a study into endometriosis. The samples will be...

  Markets are less volatile as traders anticipate easing of rates But the path in Australia may not be that easy, says CIO at Martin Currie Aussie CPI data to grab economics headlines this week   The ASX is set to have another crack at a...

The ASX200 has closed the trading day just above even. The sectors were split, with Financials leading gains, adding about half a per cent, while the Real Estate sector took a big hit ahead of this week’s interest rates decisions here an...

World Overnight SPI Overnight 7729.00 + 14.00 0.18% S&P ASX 200 7712.50 + 8.30 0.11% S&P500 5175.27 + 57.33 1.12% Nasdaq Comp 16265.64 + 246.36 1.54% DJIA 39005.49 + 235.83 0.61% S&P500 VIX 13.84 – 1.38 – 9.07% U...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.11% to 7,712.50. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotify...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. It involves betting that the stock market’s recent winners will remain winners. One of the best known momentum traders in the world is hedge f...

Predictive diagnostics company Proteomics International Laboratories (ASX:PIQ) has successfully retained its ISO 13485 certification, an internationally recognised standard for safety and quality management systems in the manufactur...

Proteomics International Laboratories will continue important research and development for its diagnostic test products after meeting key guidelines set by the International Organisation for Standardisation.

Proteomics International Laboratories’ 66 per cent-owned subsidiary OxiDx has been awarded a European patent for its finger-prick technology used in monitoring and measuring levels of oxidative stress.

Proteomics International Laboratories (ASX:PIQ) subsidiary, OxiDx, has secured a patent across 19 major European countries for its platform technology designed to assess oxidative stress Oxidative stress has diverse applications, ranging...

  Neuren’s Daybue sales meet target Proteomics granted patent in Europe Nyrada’s brain injury drug shows efficacy in animal testing   Neuren’s Daybue sales meet target, crushing short seller’s claims Neuren Pharma (ASX:NEU) says Q4 2023 s...

  Expert says buy US bonds now to lock in yields Viking Therapeutics doubled and Janux Therapeutics tripled after updates Microsoft makes another huge AI bet   The ASX is poised to open slightly higher on Wednesday after a mixed session...

The United States’ biggest government-funded healthcare provider Medicare has locked in a payment rate of US$390.75 for Proteomics International Laboratories’ PromarkerD test for diabetic kidney disease.

Alterity Therapeutics gets firm commitments for $4.8 million in capital raise Mesoblast partners with the Blood and Marrow Transplant Clinical Trials Network for pivotal trial Centers for Medicare & Medicaid Services (CMS) in US confir...

Proteomics International Laboratories’ share price has hit a seven-month high after a United States federal health agency set a national reimbursement price for the company’s “PromarkerD” diabetes test.

PIQ came out of trading suspension and surged 13pc PIQ says the US has set a national reimbursement price for PromarkerD Kazia awarded a late breaking oral presentation for paxalisib   Proteomics International Laboratories (ASX:PIQ) surge...

Stockhead’s Top 10 at shortly-before-11-ish, produced in a tearing rush because it’s the Friday before a long weekend in the middle of the school holidays so of course everyone’s got ‘the flu’, or their grandma has died for the third time t...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create uncertainty Fitch Ratings Agency downgraded the credit rating of Ramsay Health Care (ASX:RHC) to BBB- from BBB Botanix Pharmaceuticals expects...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

ASX 200 ends sharply lower on Monday, down 0.67% All Sectors  close in the red, with InfoTech taking the worst of the damage Small caps led by lithium minnows RR1, WC8 and VCM Australian shares have joined most Asian markets in a retre...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

ASX health sector fall in line with broader markets as macroeconomic factors create uncertainty Clinuvel down as its European label expansion of SCENESSE knocked back pending further data 2023 biotech market darling elevated to the S&P...

Proteomics International (PIQ) is preparing to present its latest results from the company’s novel blood test for oesophageal adenocarcinoma The company will showcase results from its PromarkerEso blood test at the 19th ISDE World Congre...

Proteomics International Laboratories has revealed new results showing that refinement of its simple “PromarkerEso” blood test correctly identified 89 per cent of patients with a type of oesophageal cancer.

Futures indicate the ASX is poised to open lower this morning as Wall Street grapples with the repercussions of China’s potential ban on Apple iPhones. Meanwhile, Australia’s regulator, ASIC, has filed a lawsuit against the country’s lar...

ASX to open flat after a mixed session on Wall Street Semiconductor stocks slumped in US and Europe after China’s iPhone ban This expert says small caps are undervalued   Australian shares are set for a muted open on Friday after a mixed...

Proteomics International Laboratories has been granted a breakthrough patent in Japan for its finger prick technology that determines oxidative stress protein biomarkers implicated in chronic diseases.

Genetic Signatures jumps on FDA 510(k) application Allegra says FDA has questions related to its 510(k) application Proteomics granted patent in Japan   Genetic Signatures jumps almost 20pc on FDA update There were a couple of FDA-related...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ALG)) - Ardent Leisure ((ABB)) - Aussie Broadband ((AFG)) - Australian Finance Group ((AVG)) - Australian Vintage ((BVS)) - Bravura Solutions ((CBO)) - Cobram Estate Oli...

Proteomics International Laboratories has seen its cash receipts from clients increase by 5.8 per cent to $198,000 in the June quarter, as the company eyes its first sales in the United States in December.

Trailblazing medtech Proteomics International Laboratories has been chosen to put its oesophageal cancer blood test on global show at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada.

EBR announces positive results of its pivotal SOLVE-CRT trial at Heart Rhythm 2023 in US EBR latest ASX biotech company to achieve a key catalyst, opening door to US$2.5 billion market Company now working on regulatory and commercialisatio...

ASX health stocks rise in the past five days outperforming broader markets Avita Medical product sales up 40% on pcp to US$10.5 million in Q1 FY23 Proteomics International Laboratories inks a deal with Sonic Healthcare USA Healthcare and...